Semaglutide for PCOS is an off-label use with growing interest and expanding evidence. Polycystic ovary syndrome affects an estimated 8–13% of reproductive-age women, and insulin resistance, weight gain, and metabolic dysfunction sit at the center of its pathophysiology. Because semaglutide improves insulin sensitivity and produces clinically meaningful weight loss, clinicians are increasingly prescribing it off-label for women with PCOS — particularly those who have not achieved adequate response to lifestyle change and metformin.
What PCOS Is and How It Intersects With Weight
PCOS is defined by some combination of irregular ovulation, elevated androgens (clinically or biochemically), and polycystic ovarian morphology on ultrasound. But PCOS is not only a reproductive diagnosis. The NIH’s National Institute of Child Health and Human Development describes PCOS as a lifelong metabolic condition associated with insulin resistance, higher risk of type 2 diabetes, dyslipidemia, and non-alcoholic fatty liver disease.
Roughly 40–80% of women with PCOS are overweight or have obesity. In those women, modest weight loss — even 5% of body weight — has been shown to improve ovulation, reduce androgen levels, and lower metabolic risk. That is the foundation on which GLP-1 research in PCOS is built.
Why GLP-1s Are Being Studied in PCOS
Semaglutide’s mechanisms address several PCOS-relevant pathways at once. It lowers fasting and post-meal glucose, improves hepatic and peripheral insulin sensitivity, slows gastric emptying, and reduces appetite through central nervous system effects. Insulin resistance is now widely considered a driver of the elevated androgens in PCOS — hyperinsulinemia stimulates ovarian androgen production and suppresses sex-hormone-binding globulin. Reducing insulin resistance can, in turn, reduce free testosterone.
What the Evidence Shows
Randomized controlled trials specifically for PCOS are limited, but the available data are encouraging. A meta-analysis published in Frontiers in Endocrinology pooled small trials of GLP-1 receptor agonists in women with PCOS and found significantly greater weight loss, reductions in waist circumference, improvements in HOMA-IR (a marker of insulin resistance), and modest decreases in free androgen index compared with metformin or placebo. Individual semaglutide studies, while small, report average weight loss between 7% and 12% over six to twelve months.
The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS recommends considering GLP-1 receptor agonists in women with PCOS and obesity for weight and metabolic management, while noting they are not approved for PCOS specifically.
Clinical Outcomes Seen in PCOS Studies
| Outcome | Typical change on semaglutide | What it means for PCOS |
|---|---|---|
| Body weight | 7%–12% reduction at 6–12 mo | Improves ovulation and metabolic risk |
| Waist circumference | 5–10 cm reduction | Reduces central adiposity tied to insulin resistance |
| HOMA-IR | 30%–40% reduction | Improves insulin sensitivity |
| Fasting glucose | 5–15 mg/dL decrease | Lowers progression to type 2 diabetes |
| Menstrual regularity | Improved in many | Increases fertility |
| Free androgen index | Modest decrease | May reduce acne, hirsutism |
Where Semaglutide Fits in PCOS Treatment
Lifestyle change — a Mediterranean or lower-glycemic dietary pattern, regular aerobic and resistance activity, and adequate sleep — remains the foundation of PCOS management. Metformin is commonly prescribed to improve insulin sensitivity and, in some women, restore ovulation. GLP-1 receptor agonists are typically considered when BMI is elevated, when metformin has not delivered adequate weight loss, or when insulin resistance and metabolic risk remain high despite first-line measures. Some clinicians use semaglutide and metformin together.
Pregnancy, Fertility, and Contraception
This is the most important PCOS-specific consideration. Semaglutide is not approved for use during pregnancy, and animal studies show fetal risk at clinically relevant doses. Women who plan to conceive should stop semaglutide at least two months before attempting pregnancy. Paradoxically, women with PCOS and obesity often become significantly more fertile as they lose weight, so pregnancy can occur unexpectedly. Reliable contraception — and honest discussion of reproductive goals — is essential.
Oral hormonal contraceptives may be less reliably absorbed during semaglutide titration and after each dose increase because of delayed gastric emptying. Talk with your clinician about whether a non-oral method is appropriate during initiation.
Side Effects to Expect
The side-effect profile in PCOS matches the general population: nausea, vomiting, diarrhea, constipation, and abdominal pain are most common, particularly during titration. Less common risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, and a boxed warning for medullary thyroid tumors. Hypoglycemia is uncommon with semaglutide alone but increases when combined with insulin or sulfonylureas.
Who Is Not a Candidate
- Women with personal or family history of medullary thyroid carcinoma or MEN 2
- Women with a history of pancreatitis
- Women who are pregnant, trying to conceive within two months, or breastfeeding
- Women with severe gastroparesis or significant gastrointestinal disease
- Women with unmanaged diabetic retinopathy (for Ozempic specifically)
Tying It Back to Prediabetes
Women with PCOS are at higher risk for developing type 2 diabetes, and many are first identified with abnormal glucose at routine screening. If your workup shows A1C in the prediabetes range, our broader treatment overview and nutrition guides provide the foundational steps that apply whether or not a GLP-1 is added. You may also find our overview of whether prediabetes is reversible helpful for framing expectations.
The Bottom Line
Semaglutide for PCOS is promising but off-label, with small studies showing meaningful weight loss and improvements in insulin sensitivity, ovulation, and androgen levels. It is not a standalone PCOS treatment and does not replace lifestyle change or address every aspect of the syndrome. Decisions about trying semaglutide for PCOS should be made with a clinician who can weigh pregnancy plans, contraceptive reliability, contraindications, and your full metabolic picture.
